• Management Team

    Day-to-Day Leadership of Gregor

    Steve Weinstein

    Chief Executive Officer

    Mr. Weinstein brings over 20 years of experience as a CEO, entrepreneur, and venture investor across biotech, medical devices, and digital health innovation. As Managing Director of the Novartis Venture Fund for twelve years, he was actively engaged in all investment decisions across the $800M global portfolio, managed the medical device practice, and invested in biotech. Prior to Novartis, he was with Prism Venture Partners, and was a Kauffman Fellow with Mid-Atlantic Venture Funds. Mr. Weinstein holds an M.B.A. with distinction from the University of Michigan Business School and a B.S. in mechanical engineering from Columbia University.

    Duncan Whitney

    Chief Scientific Officer

    Mr. Whitney joined Gregor as the Chief Scientific Officer in 2022. He has over 25 years experience developing clinical diagnostics and biotechnology products. Prior to joining Gregor he was one of the founding members of the Lung Cancer Initiative at Johnson & Johnson as the Head of Early Detection, leading global efforts aimed at diagnosing lung cancer at early stages in order to more effectively intercept and treat patients. He previously spent several years leading lung cancer studies at Allegro Diagnostics, and Veracyte (which acquired Allegro in 2014). Mr. Whitney held scientific leadership roles in a number of other emerging diagnostics, pharmaceutical, and biotechnology companies, including Curis (VP Diagnostics), U.S. Genomics (VP R&D), Exact Sciences (VP Technology Development), and Perseptive Biosystems (now part of Thermo Fisher Scientific). He received his PhD at the Massachusetts Institute of Technology, and his B.A from Colby College.

    Tobias Zutz

    Chief Technology Officer / Founder

    Mr. Zutz founded Gregor Diagnostics in 2016 and served for 5 years as its founding CEO. In 2021 he transitioned to Chief Technology Officer to focus more directly on the technology for Gregor's testing. Prior to founding Gregor he had a decade of R&D experience in assay development and molecular diagnostics. Most recently he was a member of the R&D team at Exact Sciences that developed Cologuard, a non-invasive screening test for colorectal cancer. Prior to Exact, Mr. Zutz was with two small Madison-area biotech companies. He completed a BS in Biochemistry and Genetics and an MS in Biotechnology both from the University of Wisconsin.

    Mike Bress

    Chief Financial Officer

    Mike Bress has over 30 years of experience building and leading high-performing accounting, financial, and operational teams. In recent years, he has operated as a fractional CFO/COO with a practice focused on venture- and private equity-backed companies in health care, financial services, asset management, software/hardware, B2B services, consumer products, and renewable energy. Prior to that, as CFO and/or COO for organizations ranging from tech-related start-ups to multi-billion-dollar asset management companies (including a stint as “CFO” of a US Navy submarine), he has encountered and solved most accounting, financial, technology, operational, and staff-related problems. As a financial strategist and consultant, Mike has helped over 100 clients across multiple industries maximize value through in-depth financial analysis, execution of complex transactions, and business process reengineering. Mike has a degree in Economics from the University of Pennsylvania and an MBA from Georgetown University.

    Emily Breunig

    Director of Clinical and Regulatory

    Ms. Breunig has more than a decade of experience in clinical research in both academic and industry settings. She has worked the last 8 years in biotech start-up companies. She has vast experience in research, clinical trials, regulatory compliance and data analysis. Ms. Breunig completed her BS in Biology from the University of Wisconsin- Madison.

    Mohsen Nabian

    Director of Data Sciences

    Mr. Nabian joined Gregor as the Director of Data Sciences in December or 2022. His passion is to use AI to fight diseases and improve lives. Mr. Nabian has several years of experience in academia and industry as an AI/Machine Learning software developer for biomedical applications. He has extensive experience in deep learning, machine learning, software engineering and bioinformatics. Prior to Gregor he was a Machine Learning Scientist for Philips and a Research Fellow at the Broad Institute. While at the Broad Mr. Nabian was the lead Developer of AMARETTO, and end-to-end software with novel machine learning algorithms for the integration and inference of multi-modal high dimensional data including multi-omics in genomics, imaging and clinical data. Mr. Nabian has a Ph.D. in Engineering Science and M.Sc. in Computer Science both from Northeastern University.

  • Board of Directors

    Experienced Leaders to help shape the future of Gregor

    Lauren Tyra, PhD

    Chief Scientific Officer, Green Park & Golf Ventures

    Michael Partsch

    Chief Venture Officer, WARF

    Mike Partsch is a seasoned medical device venture capitalist and startup CEO bringing extensive operational experience in early-stage university spinouts. His career has included stops at Versant Ventures – a top health care venture fund – and Acuitive Medical Ventures (AMV), which he started. Partsch currently manages the multimillion-dollar WARF Ventures fund, which invests in companies founded to commercialize UW-Madison or Morgridge Institute for Research technologies. Partsch holds an MBA from Carnegie Mellon University, and completed a Kauffman Fellowship.

    Sundu Brahmasandra, PhD

    Independent Director

    Sundu Brahmasandra is an accomplished serial entrepreneur and brings more than 20 years of impressive leadership in all aspects of novel IVD product development, strategic planning, and operational management. Most recently Sundu was the President & COO of NeuMoDx Molecular where he led the development of a multitude of molecular diagnostics assays on the revolutionary NeuMoDx 288 and NeuMoDx 96 Molecular Systems. Prior to NeuMoDx Sundu co-founded HandyLab, Inc and led the development of the HandyLab Jaguar System. Sundu holds a B.Tech in Chemical Engineering from IIT-Madras and a PhD in Chemical Engineering from the University of Michigan, Ann Arbor.

    Steve Weinstein

    Gregor Diagnostics CEO

    Tobias Zutz

    Gregor Diagnostics CTO and Founder

  • Investors

    Thankful to have investors involved in Gregor beyond just a check!

All Posts